Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Next Previous
Search
Trial Profile

A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms KEYNOTE-087
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 19 Sep 2024 This trial has been completed in Spain (Global end date:2023-09-18) according to European Clinical Trials Database record.
    • 29 Sep 2023 Status changed from active, no longer recruiting to completed.
    • 15 Jun 2023 Results of post hoc analysis assessing relative efficacy of favezelimab + pembrolizumab (n=27 from MK-4280-003 study) compared with pembrolizumab alone (n=123 from study KEYNOTE 087) in patients with PD-1 refractory R/R cHL presented at the 28th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top